Literature DB >> 3065347

Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum.

H Hosotsubo1, S Takahara, N Taenaka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3065347     DOI： 10.1016/s0378-4347(00)80663-5

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  10 in total

1.  Population pharmacokinetics of mizoribine in pediatric recipients of renal transplantation.

Authors:  Kazuya Ishida; Osamu Motoyama; Seiichiro Shishido; Kazuo Tsuzuki; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2012-02-25       Impact factor: 2.801

2.  Population pharmacokinetics of mizoribine in adult recipients of renal transplantation.

Authors:  Kazuya Ishida; Masahiko Okamoto; Michio Ishibashi; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2011-07-14       Impact factor: 2.801

3.  The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease.

Authors:  Takuhito Nagai; Osamu Uemura; Hisashi Kaneda; Katsumi Ushijima; Kazuhide Ohta; Yoshimitsu Gotoh; Kenichi Satomura; Masaki Shimizu; Mikiya Fujieda; Masashi Morooka; Takuji Yamada; Masayoshi Yamada; Naohiro Wada; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2016-11-21       Impact factor: 2.801

4.  Assessment of factors associated with mizoribine responsiveness in children with steroid-dependent nephrotic syndrome.

Authors:  Tomomi Kondoh; Yohei Ikezumi; Katsuyuki Yokoi; Yoko Nakajima; Yuji Matsumoto; Masahiro Kaneko; Hiroya Hasegawa; Takeshi Yamada; Naonori Kumagai; Tetsuya Ito; Tetsushi Yoshikawa
Journal:  Clin Exp Nephrol       Date:  2019-06-11       Impact factor: 2.801

5.  The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients.

Authors:  Norio Yoshimura; Hidetaka Ushigome; Kiyokazu Akioka; Syuuji Nobori; Tomoyuki Suzuki; Kazuki Sakai; Masahiko Okamoto
Journal:  Clin Exp Nephrol       Date:  2012-08-02       Impact factor: 2.801

6.  Usefulness of mizoribine administration in children with frequently relapsing nephrotic syndrome, and the relationship between pharmacokinetic parameters and efficacy: a multicenter prospective cohort study in China.

Authors:  Zheng-Kun Xia; Yuan-Fu Gao; Li-Ping Rong; Xi-Qiang Dang; Qian Shen; Xiao-Yun Jiang; Zhu-Wen Yi; Hong Xu
Journal:  World J Pediatr       Date:  2019-03-12       Impact factor: 2.764

7.  Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers.

Authors:  Daria Stypinski; Mohammad Obaidi; Michelle Combs; Meg Weber; Adrian J Stewart; Hiroaki Ishikawa
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

8.  Population pharmacokinetics of mizoribine in pediatric patients with kidney disease.

Authors:  Hisashi Kaneda; Masaki Shimizu; Kazuhide Ohta; Katsumi Ushijima; Yoshimitsu Gotoh; Kenichi Satomura; Takuhito Nagai; Mikiya Fujieda; Masashi Morooka; Takuji Yamada; Masayoshi Yamada; Naohiro Wada; Mari Takaai; Yukiya Hashimoto; Osamu Uemura
Journal:  Clin Exp Nephrol       Date:  2015-12-09       Impact factor: 2.801

9.  Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome.

Authors:  Takao Saito; Masayuki Iwano; Koichi Matsumoto; Tetsuya Mitarai; Hitoshi Yokoyama; Noriaki Yorioka; Shinichi Nishi; Ashio Yoshimura; Hiroshi Sato; Satoru Ogahara; Yoshie Sasatomi; Yasufumi Kataoka; Shiro Ueda; Akio Koyama; Shoichi Maruyama; Masaomi Nangaku; Enyu Imai; Seiichi Matsuo; Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2016-10-25       Impact factor: 2.801

Review 10.  Structural and functional imaging markers for susceptibility to psychosis.

Authors:  Christina Andreou; Stefan Borgwardt
Journal:  Mol Psychiatry       Date:  2020-02-17       Impact factor: 15.992
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.